



**SCIENTIFIC PROGRAMME**  
**II GO NORTE INTERNATIONAL GU DEBATES**

**THURSDAY, OCTOBER 5<sup>th</sup>**

- 09.30-10.00**      **REGISTRATION**
- 10.00**              **OPENING**  
Dr. Ignacio Durán, Medical Oncology Department, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander  
Dr. Nuria Lainez, Medical Oncology Department, Hospital Universitario de Navarra, Pamplona
- 10.15-11.45**      **PERIOPERATIVE TREATMENT IN GU ONCOLOGY: THE DEBATE IS OPEN  
THE CASE OF BLADDER CANCER**  
Chairs:  
Dr. Enrique Grande, Medical Oncology Department, MD Anderson Cancer Center Madrid  
Dr. Mario Álvarez Maestro, Urology Department, Hospital Universitario La Paz, Madrid
- 10.15-10.25**      **Questions to audience (Interactive Voting)**  
**CASE 1 – to be confirmed**
- 10.25-10.40**      **IO based perioperative treatment in muscle invasive bladder cancer:  
in favor**  
Dr. M<sup>e</sup> José Juan, Medical Oncology Department, Instituto Valenciano de Oncología, Valencia
- 10.40-10.55**      **IO based perioperative treatment in muscle invasive bladder cancer:  
the critical approach**  
Dr. Alfonso Gómez de Liaño, Medical Oncology Department, Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran Canaria  
**Voting**
- 10.55-11.15**      **Perioperative treatment in muscle invasive bladder cancer:  
the expert's vision**  
**TBC**



11.15-11.45

*Discussion*

**11.45-12.15**

**COFFEE BREAK**

**12.15-13.45**

**THE CASE OF KIDNEY CANCER**

Chairs:

Dr. Pablo Maroto, Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona

Dr. Felipe Villacampa, Urology Department, Clínica Universidad de Navarra, Madrid

12.15-12.25

**Questions to audience (Interactive Voting)**

**CASE 1 – to be confirmed**

12.25-12.40

**IO based perioperative treatment in localized renal cell cancer: in favor**

Dr. Javier Puente, Medical Oncology Department, Hospital Clínico San Carlos, Madrid

12.40-12.55

**IO based perioperative treatment in localized renal cell cancer: the critical approach**

Dr. Guillermo de Velasco, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid

**Voting**

12.55-13.15

**IO based perioperative treatment in localized RCC: the expert's vision**  
**TBC**

13.15-13.45

*Discussion*

**13.45-14.30**

**MEET WITH THE EXPERT SYMPOSIUM**

**14.30-16.00**

**LUNCH COCKTAIL**

**16.00-17.25**

**CHALLENGING STANDARDS OF CARE IN BLADDER CANCER TREATMENT**

Chairs:

Dr. Daniel Castellano, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid

Dr. Albert Font, Medical Oncology Department, Hospital Universitari Germans Trias y Pujol, Institut Català d'Oncologia, Badalona



- 16.00-16.15      **The BCG refractory scenario: are the upcoming strategies good enough to replace the standard?**  
Dr. Félix Guerrero, Urology Department, Hospital Universitario 12 de Octubre, Madrid
- 16.15-16.35      **Are ADCs combinations the new backbone in first line mUC?**  
Dr. Petros Grivas, Medical Oncology Department, Genitourinary Cancers Program, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Center
- 16.35-16.55      **Are the Galsky criteria getting old fashioned in 2023? Are we going to stratify patients in first line in the near future?**  
Dr. Yohann Loriot, Medical Oncology Department, Institut Gustave Roussy, Villejuif, France
- 16.55-17.25      *Discussion*
- 17.25-17.55      COFFEE BREAK**
- 17.55-19.25      THINKING OUTSIDE OF THE BOX: OPPORTUNITIES FOR COLLABORATION**  
Chairs:  
Dr. Laura Basterretxea, Medical Oncology Department, Hospital Universitario Donostia  
Dr. Ricardo Fernández, Medical Oncology Department, Instituto Oncológico IMQ Zorrotzaurre, Hospital Universitario de Cruces, Bizkaia
- 17.55-18.10      **Physical exercise and cancer: a possible duet in GU oncology?**  
Mr. Mario Redondo, Physiotherapist, Exercise Physiology Cancer Center, Madrid
- 18.10-18.25      **New technologies and prostate cancer patients: is it feasible?**  
Mr. Borja Gómez Mediavilla, Research Nurse, Instituto de Investigación Sanitaria – IDIVAL, Santander
- 18.25-18.40      **Managing elderly GU oncology patients: am I missing something?**  
Dr. Regina Gironés, Medical Oncology Department, Hospital Universitario Politècnic La Fe, Valencia
- 18.40-18.55      **Oligometastatic disease in GU oncology: facts and “myths”**  
Dr. Alfonso Gómez de Iturriaga, Radiation Oncology Department, Hospital Universitario de Cruces, Bizkaia
- 18.55-19.25      *Discussion*



**19.25-20.10      A LOOK INTO THE NEAR FUTURE**

**Chair:**

Dr. Álvaro Pinto, Medical Oncology Department, Hospital Universitario La Paz, Madrid

**TBC**

Mr. Mauro A. Fuentes, Social Media & Innovation, Ogilvy, Madrid

**20.10-20.20      CLOSING OF THE DAY**

**FRIDAY, OCTOBER 6th**

**08.30              OPENING**

Dr. Ignacio Durán, Medical Oncology Department, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander

Dr. Nuria Lainez, Medical Oncology Department, Hospital Universitario de Navarra, Pamplona

**08.35-09:45      ADVANCED KIDNEY CANCER: FROM THE CLINIC TO THE BASIC SCIENCE**

**Chairs:**

Dr. Jesús García-Donas, Medical Oncology Department, Hospital Universitario HM Sanchinarro - Centro Integral Oncológico Clara Campal HM CIOCC, Madrid

Dr. Teresa Alonso, Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid

**08.35-08.55      Certainties and doubts in first-line mRCC**

Dr. Viktor Grünwald, Medical Oncology Department, University Hospital Essen, Germany

**08.55-09:15      Understanding the dynamics of renal cell cancer evolution to improve therapeutics**

Dr. Charlotte Spencer, Research Department of Pathology, Cancer Dynamics Laboratory, Francis Crick Institute, Renal and Skin Unit, The Royal Marsden Hospital, London

**09.45-09.30      Characterizing rare renal cell cancers to guide treatment**

Dr. Cristina Rodríguez-Antona, Established Investigator, Centro Nacional de Investigaciones Oncológicas-CNIO, Madrid

**09:30-09:45      Discussion**




OCTOBER 5<sup>th</sup>-6<sup>th</sup>, 2023

Organized by:



- 09.45-11:05**      **PROSTATE CANCER: CHALLENGES IN 2023**  
Chairs:  
Dr. Joan Carles, Medical Oncology Department, Hospital Universitari Vall d'Hebron, Barcelona  
Dr. Mario Domínguez, Urology Department, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander
- 09.45-10.00      **PARPi: the debate is open**  
**CASE – to be confirmed**
- 10.00-10.15      **PARPi: the selection does not matter to me**  
Dr. David Lorente, Medical Oncology Department, Hospital Provincial de Castellón
- 10.15-10.30      **PARPi: the selection does matter to me**  
Dr. Elena Castro, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid
- 10.30-10.50      **PARP inhibition and patient selection: integrating basic science**  
**And Clinical data**
- ONLINE**      Dr. Johann Sebastian de Bono, Medical Oncology Department, The Institute of Cancer Research and Royal Marsden, London, UK
- 10.50-11.05      *Discussion*
- 11.05-11.35**      **COFFEE BREAK**
- 11.35- 12:20**      **MEET WITH THE EXPERT- SYMPOSIUM**
- 12.20-13:30**      **ADVANCED HORMONE-SENSITIVE PROSTATE CANCER**  
Chairs:  
Dr. Carmen Santander, Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza  
Dr. Juan Francisco Rodríguez Moreno, Medical Oncology Department, Hospital Universitario HM Sanchinarro - Centro Integral Oncológico Clara Campal HM CIOCC, Madrid
- 12.20-12.35**      **A triplet is my standard of care for all mHSPC patients**  
Dr. Enrique González-Billalabeitia, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid



- 12.35-12.50**     **I select very carefully my mHSPC patients for a triplet**  
Dr. Miguel Ángel Climent, Medical Oncology Department, Instituto Valenciano de Oncología, Valencia
- 12.50-13.10**     **Patient selection in mHSPC : Integrating current data**  
Dr. Bertrand Tombal, Urology Department, Université Catholique de Louvain, Belgium
- 13.10-13.30**     *Discussion*
- 13.30-14:20**     **THERAGNOSIS IN PROSTATE CANCER: WHERE ARE WE IN 2023?**  
Chair:  
Dr. José Luis Pérez Gracia, Medical Oncology Department, Clínica Universidad De Navarra, Pamplona
- 13.30-13:45**     **What a clinician should know about PSMA PET in prostate cancer:  
Success and pitfalls**  
Dr. Antonio Maldonado, Nuclear Medicine Department, Hospital Universitario Quirónsalud Madrid
- 13.45-14.00**     **What can I expect from theragnosis in prostate cancer: the clinician's  
Perspective**  
Dr. Josep M<sup>a</sup> Piulats, Medical Oncology Department, Institut Català d'Oncologia Hospital Duran i Reynals, L'hospitalet de Llobregat
- 14.00-14.20**     *Discussion*
- 14.20-14.25**     **CLOSING REMARKS**
- 14.25**             **FAREWELL COCKTAIL**
-